TS

Thurvas Sudharsana Narayanan Arvind Kumar

Active Director Director DIN 11817501
DIN 11817501 First appointment Jul 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Thurvas Sudharsana Narayanan Arvind Kumar

Thurvas Sudharsana Narayanan Arvind Kumar is a Director at Zyphren Medtech Private Limited (since 2026).

DIN 11817501
Primary Designation Director
First Appointment 10 Jul 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zyphren Medtech Private Limited U32509MP2026PTC085358
Director10 Jul 20262026Active

Board colleagues of Thurvas Sudharsana Narayanan Arvind Kumar

NameDINCompanyDesignation
Harshita Chourasia11817502Zyphren Medtech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Zyphren Medtech Private Limited
Premium access

Shareholding and investment profile for Thurvas Sudharsana Narayanan Arvind Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Thurvas Sudharsana Narayanan Arvind Kumar

Thurvas Sudharsana Narayanan Arvind Kumar currently holds 1 directorship: Zyphren Medtech Private Limited (Director, since 10 Jul 2026).

Thurvas Sudharsana Narayanan Arvind Kumar was first appointed on 10 Jul 2026 as Director at Zyphren Medtech Private Limited.

The current boards of Thurvas Sudharsana Narayanan Arvind Kumar's companies include Harshita Chourasia (Zyphren Medtech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available